Harbor Capital Advisors Inc. Has $1.95 Million Stock Holdings in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)

Harbor Capital Advisors Inc. boosted its position in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) by 3.7% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 49,818 shares of the biopharmaceutical company’s stock after purchasing an additional 1,755 shares during the period. Harbor Capital Advisors Inc. owned 0.07% of Xenon Pharmaceuticals worth $1,953,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. JPMorgan Chase & Co. lifted its holdings in shares of Xenon Pharmaceuticals by 1,263.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 976,783 shares of the biopharmaceutical company’s stock valued at $38,456,000 after buying an additional 905,129 shares during the last quarter. Barclays PLC raised its position in Xenon Pharmaceuticals by 1,275.5% during the third quarter. Barclays PLC now owns 14,993 shares of the biopharmaceutical company’s stock valued at $590,000 after acquiring an additional 13,903 shares in the last quarter. Vestcor Inc acquired a new stake in Xenon Pharmaceuticals in the third quarter valued at approximately $327,000. Y Intercept Hong Kong Ltd grew its position in Xenon Pharmaceuticals by 68.8% in the third quarter. Y Intercept Hong Kong Ltd now owns 24,557 shares of the biopharmaceutical company’s stock worth $967,000 after acquiring an additional 10,007 shares in the last quarter. Finally, Wellington Management Group LLP increased its stake in shares of Xenon Pharmaceuticals by 0.4% during the 3rd quarter. Wellington Management Group LLP now owns 3,843,447 shares of the biopharmaceutical company’s stock worth $151,317,000 after purchasing an additional 15,226 shares during the last quarter. Hedge funds and other institutional investors own 95.45% of the company’s stock.

Xenon Pharmaceuticals Stock Down 2.9 %

Shares of NASDAQ:XENE opened at $38.41 on Friday. The company has a market cap of $2.93 billion, a price-to-earnings ratio of -13.62 and a beta of 1.20. The business has a 50 day moving average price of $40.97 and a 200 day moving average price of $40.68. Xenon Pharmaceuticals Inc. has a twelve month low of $35.53 and a twelve month high of $50.99.

Xenon Pharmaceuticals (NASDAQ:XENE) last posted its quarterly earnings data on Tuesday, November 12th. The biopharmaceutical company reported ($0.81) earnings per share for the quarter, beating the consensus estimate of ($0.82) by $0.01. During the same period in the prior year, the firm earned ($0.73) earnings per share. Analysts anticipate that Xenon Pharmaceuticals Inc. will post -3.1 EPS for the current year.

Insider Buying and Selling at Xenon Pharmaceuticals

In other Xenon Pharmaceuticals news, Director Gary Patou sold 4,891 shares of the firm’s stock in a transaction that occurred on Friday, November 22nd. The stock was sold at an average price of $41.08, for a total value of $200,922.28. Following the completion of the sale, the director now owns 23,573 shares in the company, valued at approximately $968,378.84. This trade represents a 17.18 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Sherry Aulin sold 18,709 shares of the business’s stock in a transaction that occurred on Wednesday, December 18th. The shares were sold at an average price of $41.21, for a total value of $770,997.89. The disclosure for this sale can be found here. Insiders own 5.52% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on XENE. Raymond James reiterated an “outperform” rating and issued a $50.00 price objective on shares of Xenon Pharmaceuticals in a report on Thursday, October 10th. Needham & Company LLC reiterated a “buy” rating and set a $60.00 price target on shares of Xenon Pharmaceuticals in a research note on Wednesday, November 13th. Finally, HC Wainwright reissued a “buy” rating and issued a $53.00 price objective on shares of Xenon Pharmaceuticals in a research note on Thursday, December 12th. Seven research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $56.00.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.